Frequent disruption of the RB pathway in indolent follicular lymphoma suggests a new combination therapy

Journal of Experimental Medicine

Volumn 211, Issue 7, 2014, Pages 1379-1391

  Oricchio, Elisa ^a   Ciriello, Giovanni ^a   Jiang, Man ^a   Boice, Michael H ^a   Schatz, Jonathan H ^a   Heguy, Adriana ^a   Viale, Agnes ^a   de Stanchina, Elisa ^a   Teruya Feldstein, Julie ^a   Bouska, Alyssa ^b   McKeithan, Tim ^b   Sander, Chris ^a   Tam, Wayne ^c   Seshan, Venkatraman E ^a   Chan, Wing Chung ^b   Chaganti, R S K ^a   Wendel, Hans Guido ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR 2A; CYCLIN DEPENDENT KINASE INHIBITOR 2B; PALBOCICLIB; PROTEIN P16; RETINOBLASTOMA PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER RISK; CELL PROLIFERATION; CHROMOSOME 12; COHORT ANALYSIS; CONTROLLED STUDY; DRUG POTENTIATION; ENZYME INHIBITION; FOLLICULAR LYMPHOMA; GENE DELETION; GENE DISRUPTION; GENE LOCUS; GENETIC RISK; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INDOLENT FOLLICULAR LYMPHOMA; MAJOR CLINICAL STUDY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYCLIN-DEPENDENT KINASE 4; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYCLIN-DEPENDENT KINASE INHIBITOR P16; HUMANS; LYMPHOMA, FOLLICULAR; MALE; MICE; NEOPLASMS, EXPERIMENTAL; PROTO-ONCOGENE PROTEINS C-BCL-2; RETINOBLASTOMA PROTEIN;

EID: 84903776028     PISSN: 00221007     EISSN: 15409538     Source Type: Journal    
DOI: 10.1084/jem.20132120     Document Type: Article

References (44)

1. 1000 Genomes Project Consortium, G.R. Abecasis, A. Auton, L.D. Brooks, M.A. DePristo, R.M. Durbin, R.E. Handsaker, H.M. Kang, G.T. Marth, and G.A. McVean. 2012. An integrated map of genetic variation from 1,092 human genomes. Nature. 491:56-65. http://dx.doi.org/10.1038/nature11632
2. Beroukhim, R., C.H. Mermel, D. Porter, G. Wei, S. Raychaudhuri, J. Donovan, J. Barretina, J.S. Boehm, J. Dobson, M. Urashima, et al. 2010 The landscape of somatic copy-number alteration across human cancers. Nature. 463:899-905. http://dx.doi.org/10.1038/nature08822
3. Bödör, C., V. Grossmann, N. Popov, J. Okosun, C. O'Riain, K. Tan, J. Marzec, S. Araf, J. Wang, A.M. Lee, et al. 2013 EZH2 mutations are frequent and represent an early event in follicular lymphoma. Blood. 122:3165-3168. http://dx.doi.org/10.1182/blood-2013-04-496893
4. Bouska, A., T.W. McKeithan, K.E. Deffenbacher, C. Lachel, G.W. Wright, J. Iqbal, L.M. Smith, W. Zhang, C. Kucuk, A. Rinaldi, et al. 2014 Genome-wide copy-number analyses reveal genomic abnormalities involved in transformation of follicular lymphoma. Blood. 123:1681-1690. http://dx.doi.org/10.1182/blood-2013-05-500595
5. Ciriello, G., E. Cerami, C. Sander, and N. Schultz. 2012 Mutual exclusivity analysis identifies oncogenic network modules. Genome Res. 22:398-406. http://dx.doi.org/10.1101/gr.125567.111
6. Egle, A., A.W. Harris, M.L. Bath, L. O'Reilly, and S. Cory. 2004 VavP-Bcl2 transgenic mice develop follicular lymphoma preceded by germinal center hyperplasia. Blood. 103:2276-2283. http://dx.doi.org/10.1182/blood-2003-07-2469
7. Elenitoba-Johnson, K.S., R.D. Gascoyne, M.S. Lim, M. Chhanabai, E.S. Jaffe, and M. Raffeld. 1998 Homozygous deletions at chromosome 9p21 involving p16 and p15 are associated with histologic progression in follicle center lymphoma. Blood. 91:4677-4685.
8. Fitzgerald, J.B., B. Schoeberl, U.B. Nielsen, and P.K. Sorger. 2006 Systems biology and combination therapy in the quest for clinical efficacy. Nat. Chem. Biol. 2:458-466. http://dx.doi.org/10.1038/nchembio817
9. Flaherty, K.T., P.M. Lorusso, A. Demichele, V.G. Abramson, R. Courtney, S.S. Randolph, M.N. Shaik, K.D. Wilner, P.J. O'Dwyer, and G.K. Schwartz. 2012 Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin. Cancer Res. 18:568-576. http://dx.doi.org/10.1158/1078-0432.CCR-11-0509
10. Fry, D.W., P.J. Harvey, P.R. Keller, W.L. Elliott, M. Meade, E. Trachet, M. Albassam, X. Zheng, W.R. Leopold, N.K. Pryer, and P.L. Toogood. 2004 Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3:1427-1438.
11. Futreal, P.A., L. Coin, M. Marshall, T. Down, T. Hubbard, R. Wooster, N. Rahman, and M.R. Stratton. 2004 A census of human cancer genes. Nat. Rev. Cancer. 4:177-183. http://dx.doi.org/10.1038/nrc1299
12. Green, M.R., A.J. Gentles, R.V. Nair, J.M. Irish, S. Kihira, C.L. Liu, I. Kela, E.S. Hopmans, J.H. Myklebust, H. Ji, et al. 2013 Hierarchy in somatic mutations arising during genomic evolution and progression of follicular lymphoma. Blood. 121:1604-1611. http://dx.doi.org/10.1182/blood-2012-09-457283
13. Grønbaek, K., P. de Nully Brown, M.B. Møller, T. Nedergaard, E. Ralfkiaer, P. Møller, J. Zeuthen, and P. Guldberg. 2000 Concurrent disruption of p16INK4a and the ARF-p53 pathway predicts poor prognosis in aggressive non-Hodgkin's lymphoma. Leukemia. 14:1727-1735. http://dx.doi.org/10.1038/sj.leu.2401901
14. Hans, C.P., D.D. Weisenburger, J.M. Vose, L.M. Hock, J.C. Lynch, P. Aoun, T.C. Greiner, W.C. Chan, R.G. Bociek, P.J. Bierman, and J.O. Armitage. 2003 A significant diffuse component predicts for inferior survival in grade 3 follicular lymphoma, but cytologic subtypes do not predict survival. Blood. 101:2363-2367. http://dx.doi.org/10.1182/blood-2002-07-2298
15. Hsi, E.D., I. Mirza, G. Lozanski, J. Hill, B. Pohlman, M.T. Karafa, and R. Coupland. 2004 A clinicopathologic evaluation of follicular lymphoma grade 3A versus grade 3B reveals no survival differences. Arch. Pathol. Lab. Med. 128:863-868.
16. Lenz, G., G.W. Wright, N.C. Emre, H. Kohlhammer, S.S. Dave, R.E. Davis, S. Carty, L.T. Lam, A.L. Shaffer, W. Xiao, et al. 2008 Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways. Proc. Natl. Acad. Sci. USA. 105:13520-13525. http://dx.doi.org/10.1073/pnas.0804295105
17. Llanos, M., H. Alvarez-Argüelles, R. Alemán, J. Oramas, L. Diaz-Flores, and N. Batista. 2001 Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma. Med. Oncol. 18:15-22. http://dx.doi.org/10.1385/MO:18:1:15
18. Martin, A.R., D.D. Weisenburger, W.C. Chan, E.I. Ruby, J.R. Anderson, J.M. Vose, P.J. Bierman, M.A. Bast, D.T. Daley, and J.O. Armitage. 1995 Prognostic value of cellular proliferation and histologic grade in follicular lymphoma. Blood. 85:3671-3678.
19. Martinez, A.E., L. Lin, and C.H. Dunphy. 2007 Grading of follicular lymphoma: comparison of routine histology with immunohistochemistry. Arch. Pathol. Lab. Med. 131:1084-1088.
20. Matsushime, H., M.E. Ewen, D.K. Strom, J.Y. Kato, S.K. Hanks, M.F. Roussel, and C.J. Sherr. 1992 Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell. 71:323-334. http://dx.doi.org/10.1016/0092-8674(92)90360-O
21. Mermel, C.H., S.E. Schumacher, B. Hill, M.L. Meyerson, R. Beroukhim, and G. Getz. 2011 GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol. 12:R41. http://dx.doi.org/10.1186/gb-2011-12-4-r41
22. Michaud, K., D.A. Solomon, E. Oermann, J.S. Kim, W.Z. Zhong, M.D. Prados, T. Ozawa, C.D. James, and T. Waldman. 2010 Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts. Cancer Res. 70:3228-3238. http://dx.doi.org/10.1158/0008-5472.CAN-09-4559
23. Morin, R.D., N.A. Johnson, T.M. Severson, A.J. Mungall, J. An, R. Goya , J.E. Paul, M. Boyle, B.W. Woolcock, F. Kuchenbauer, et al. 2010 Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. Nat. Genet. 42:181-185. http://dx.doi.org/10.1038/ng.518
24. Morin, R.D., M. Mendez-Lago, A.J. Mungall, R. Goya, K.L. Mungall, R.D. Corbett, N.A. Johnson, T.M. Severson, R. Chiu, M. Field, et al. 2011 Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. Nature. 476:298-303. http://dx.doi.org/10.1038/nature10351
25. Musgrove, E.A., C.E. Caldon, J. Barraclough, A. Stone, and R.L. Sutherland. 2011 Cyclin D as a therapeutic target in cancer. Nat. Rev. Cancer. 11:558-572. http://dx.doi.org/10.1038/nrc3090
26. Naderi, S., K.B. Gutzkow, H.U. Låhne, S. Lefdal, W.J. Ryves, A.J. Harwood, and H.K. Blomhoff. 2004 cAMP-induced degradation of cyclin D3 through association with GSK-3β. J. Cell Sci. 117:3769-3783. http://dx.doi.org/10.1242/jcs.01210
27. O'Reilly, L.A., D.C. Huang, and A. Strasser. 1996 The cell death inhibitor Bcl-2 and its homologues influence control of cell cycle entry. EMBO J. 15:6979-6990.
28. Okosun, J., C. Bödör, J. Wang, S. Araf, C.Y. Yang, C. Pan, S. Boller, D. Cittaro, M. Bozek, S. Iqbal, et al. 2014 Integrated genomic analysis identifies recurrent mutations and evolution patterns driving the initiation and progression of follicular lymphoma. Nat. Genet. 46:176-181. http://dx.doi.org/10.1038/ng.2856
29. Olshen, A.B., E.S. Venkatraman, R. Lucito, and M. Wigler. 2004 Circular binary segmentation for the analysis of array-based DNA copy number data. Biostatistics. 5:557-572. http://dx.doi.org/10.1093/biostatistics/kxh008
30. Oltersdorf, T., S.W. Elmore, A.R. Shoemaker, R.C. Armstrong, D.J. Augeri, B.A. Belli, M. Bruncko, T.L. Deckwerth, J. Dinges, P.J. Hajduk, et al. 2005 An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature. 435:677-681. http://dx.doi.org/10.1038/nature03579
31. Oricchio, E., G. Nanjangud, A.L. Wolfe, J.H. Schatz, K.J. Mavrakis, M. Jiang, X. Liu, J. Bruno, A. Heguy, A.B. Olshen, et al. 2011 The Eph-receptor A7 is a soluble tumor suppressor for follicular lymphoma. Cell. 147:554-564. http://dx.doi.org/10.1016/j.cell.2011.09.035
32. Pasqualucci, L., V. Trifonov, G. Fabbri, J. Ma, D. Rossi, A. Chiarenza, V.A. Wells, A. Grunn, M. Messina, O. Elliot, et al. 2011 Analysis of the coding genome of diffuse large B-cell lymphoma. Nat. Genet. 43:830-837. http://dx.doi.org/10.1038/ng.892
33. Pasqualucci, L., H. Khiabanian, M. Fangazio, M. Vasishtha, M. Messina, A.B. Holmes, P. Ouillette, V. Trifonov, D. Rossi, F. Tabbò, et al. 2014 Genetics of follicular lymphoma transformation. Cell Rep. 6:130-140. http://dx.doi.org/10.1016/j.celrep.2013.12.027
34. Phan, R.T., M. Saito, K. Basso, H. Niu, and R. Dalla-Favera. 2005 BCL6 interacts with the transcription factor Miz-1 to suppress the cyclin-dependent kinase inhibitor p21 and cell cycle arrest in germinal center B cells. Nat. Immunol. 6:1054-1060. http://dx.doi.org/10.1038/ni1245
35. Pinyol, M., F. Cobo, S. Bea, P. Jares, I. Nayach, P.L. Fernandez, E. Montserrat, A. Cardesa, and E. Campo. 1998 p16(INK4a) gene inactivation by deletions, mutations, and hypermethylation is associated with transformed and aggressive variants of non-Hodgkin's lymphomas. Blood. 91:2977-2984.
36. Relander, T., N.A. Johnson, P. Farinha, J.M. Connors, L.H. Sehn, and R.D. Gascoyne. 2010 Prognostic factors in follicular lymphoma. J. Clin. Oncol. 28:2902-2913. http://dx.doi.org/10.1200/JCO.2009.26.1693
37. Rozen, S., and H.J. Skaletsky. 2000 Primer3 on the WWW for general users and for biologist programmers. In Bioinformatics Methods and Protocols: Methods in Molecular Biology. S. Krawetz and S. Misener, editors. Humana Press, Totowa, NJ. 365-386.
38. Schatz, J.H., E. Oricchio, A.L. Wolfe, M. Jiang, I. Linkov, J. Maragulia, W. Shi, Z. Zhang, V.K. Rajasekhar, N.C. Pagano, et al. 2011 Targeting capdependent translation blocks converging survival signals by AKT and PIM kinases in lymphoma. J. Exp. Med. 208:1799-1807. http://dx.doi.org/10.1084/jem.20110846
39. Sherr, C.J. 1996 Cancer cell cycles. Science. 274:1672-1677. http://dx.doi.org/10.1126/science.274.5293.1672
40. Solal-Céligny, P., P. Roy, P. Colombat, J. White, J.O. Armitage, R. Arranz-Saez, W.Y. Au, M. Bellei, P. Brice, D. Caballero, et al. 2004 Follicular lymphoma international prognostic index. Blood. 104:1258-1265. http://dx.doi.org/10.1182/blood-2003-12-4434
41. Staudt, L.M. 2007 A closer look at follicular lymphoma. N. Engl. J. Med. 356:741-742. http://dx.doi.org/10.1056/NEJMcibr067155
42. Vairo, G., K.M. Innes, and J.M. Adams. 1996 Bcl-2 has a cell cycle inhibitory function separable from its enhancement of cell survival. Oncogene. 13:1511-1519.
43. Vairo, G., T.J. Soos, T.M. Upton, J. Zalvide, J.A. DeCaprio, M.E. Ewen, A. Koff, and J.M. Adams. 2000 Bcl-2 retards cell cycle entry through p27(Kip1), pRB relative p130, and altered E2F regulation. Mol. Cell. Biol. 20:4745-4753. http://dx.doi.org/10.1128/MCB.20.13.4745-4753.2000
44. Wendel, H.G., E. De Stanchina, J.S. Fridman, A. Malina, S. Ray, S. Kogan, C. Cordon-Cardo, J. Pelletier, and S.W. Lowe. 2004 Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy. Nature. 428:332-337. http://dx.doi.org/10.1038/nature02369